230 related articles for article (PubMed ID: 31479522)
1. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Caratelli S; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Pastore D; Cenciarelli C; Venditti A; Del Principe MI; Lauro D; Landoni E; Du H; Savoldo B; Ferrone S; Dotti G; Sconocchia G
Int J Cancer; 2020 Jan; 146(1):236-247. PubMed ID: 31479522
[TBL] [Abstract][Full Text] [Related]
2. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
4. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
5. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
6. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
[TBL] [Abstract][Full Text] [Related]
7. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
Front Immunol; 2018; 9():3124. PubMed ID: 30761158
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
9. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
[TBL] [Abstract][Full Text] [Related]
10. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
[TBL] [Abstract][Full Text] [Related]
11. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
[TBL] [Abstract][Full Text] [Related]
13. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
Kubach J; Hubo M; Amendt C; Stroh C; Jonuleit H
Int J Cancer; 2015 Feb; 136(4):821-30. PubMed ID: 24947844
[TBL] [Abstract][Full Text] [Related]
14. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.
Oppenheim DE; Spreafico R; Etuk A; Malone D; Amofah E; Peña-Murillo C; Murray T; McLaughlin L; Choi BS; Allan S; Belousov A; Passioukov A; Gerdes C; Umaña P; Farzaneh F; Ross P
Br J Cancer; 2014 Mar; 110(5):1221-7. PubMed ID: 24496456
[TBL] [Abstract][Full Text] [Related]
15. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
Ottaiano A; Scala S; Normanno N; Napolitano M; Capozzi M; Rachiglio AM; Roma C; Trotta AM; D'Alterio C; Portella L; Romano C; Cassata A; Casaretti R; Silvestro L; Nappi A; Tafuto S; Avallone A; De Stefano A; Tamburini M; Picone C; Petrillo A; Izzo F; Palaia R; Albino V; Amore A; Belli A; Pace U; Di Marzo M; Chiodini P; Botti G; De Feo G; Delrio P; Nasti G
BMC Cancer; 2019 Sep; 19(1):899. PubMed ID: 31500586
[TBL] [Abstract][Full Text] [Related]
17. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
18. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
[TBL] [Abstract][Full Text] [Related]
19. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
20. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
